Deprescribing statinsand other cardiovascular medications Barriers and facilitators
Considering the growing problematic of polypharmacy, this article summarizes barriers and facilitators to deprescribing cardiovascular medications, from the point of view of physicians and patients. Patients seem to be more open to discontinue cardiovascular medications when their physician suggests...
Gespeichert in:
Veröffentlicht in: | Revue médicale suisse 2024-03, Vol.20 (864), p.480-485 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | fre |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Considering the growing problematic of polypharmacy, this article summarizes barriers and facilitators to deprescribing cardiovascular medications, from the point of view of physicians and patients. Patients seem to be more open to discontinue cardiovascular medications when their physician suggests to do so, or if they dislike the medication. Physicians tend to consider deprescribing more if they had positive experiences with deprescribing in the past, or if their patients ask them to. The most common barrier for patients is the fear of health deterioration. Patient desire to continue with their usual medication or past negative experiences with depresecribing are frequently reported as barriers by physicians. |
---|---|
ISSN: | 1660-9379 |
DOI: | 10.53738/REVMED.2024.20.864.480 |